These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 36528890)

  • 21. Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.
    Abrahamyan L; Willan AR; Beyene J; Mclimont M; Blanchette V; Feldman BM;
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S767-73. PubMed ID: 25029970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.
    Meier N; Fuchs H; Galactionova K; Hermans C; Pletscher M; Schwenkglenks M
    Pharmacoecon Open; 2024 May; 8(3):373-387. PubMed ID: 38520664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort.
    Batsuli G; Wheeler AP; Weyand AC; Sidonio RF; Young G
    Am J Hematol; 2023 Oct; 98(10):E285-E287. PubMed ID: 37471655
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of emicizumab prophylaxis for haemophilia A with inhibitors: an adaptive health technology assessment for the Indian setting.
    Kar SS; Sivanantham P; Ravel V; Mehndiratta A; Tyagi K; Ollendorf DA
    BMJ Evid Based Med; 2024 May; ():. PubMed ID: 38719438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients.
    Hajducek DM; Chelle P; Iorio A; Iserman E; Edginton AN
    Haemophilia; 2024 Jul; 30(4):925-932. PubMed ID: 38738967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence.
    Dargaud Y; Janbain M
    J Blood Med; 2021; 12():1031-1036. PubMed ID: 34908888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.
    Abdelgawad HAH; Foster R; Otto M
    Blood Rev; 2024 Mar; 64():101164. PubMed ID: 38216442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health utilities in adults with hemophilia A: A retrospective cohort study.
    Hirniak S; Edginton AN; Iorio A; Alsabbagh MW; Hajducek DM; Wong WW
    Haemophilia; 2024 May; 30(3):733-742. PubMed ID: 38506967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of Emicizumab Therapy in an Adult Patient With Hemophilia A With Inhibitors and Associated Drug Cost Savings.
    Root AG; Raiff RD; Ortel TL; Hodulik KL
    J Pharm Technol; 2020 Jun; 36(3):110-113. PubMed ID: 37927308
    [No Abstract]   [Full Text] [Related]  

  • 30. Laboratory response to paradigm change in hemophilia treatment.
    Shafaati Lambert M; Bruzelius M; Mahmoud Hourani Soutari N; Ranta S; Antovic JP
    Clin Chem Lab Med; 2023 Nov; 61(12):e248-e250. PubMed ID: 37319338
    [No Abstract]   [Full Text] [Related]  

  • 31. Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective.
    Camelo RM; Barbosa MM; Henriques LCM; Martin AP; Godman B; Guerra Júnior AA; Acurcio FA; Alvares-Teodoro J
    Saudi Pharm J; 2023 Dec; 31(12):101867. PubMed ID: 38028212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riding the wave of change: Providing solid ground to support nursing with patient transitions to novel haemophilia therapies.
    Crilly E; Harrison C; Maahs J; Beijlevelt M; Ramsay B; Githinji C; Sisdelli M; Dsouza A
    Haemophilia; 2024 Apr; 30 Suppl 3():135-139. PubMed ID: 38549492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab.
    Lee K; Chau JQ; Suber YB; Sternberg AR; Pishko A; George LA; Bhoj V; Doshi BS; Samelson-Jones BJ
    Blood; 2024 Jul; ():. PubMed ID: 38985830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment Of Acquired Hemophilia A Using FEIBA Supplemented With Emicizumab.
    Kaunchale N; Ansari S; More A; Bansal S; Kshirsagar S; Padate B; Rangarajan S; Shetty S
    Indian J Hematol Blood Transfus; 2023 Jan; 39(1):159-160. PubMed ID: 36699438
    [No Abstract]   [Full Text] [Related]  

  • 35. Emicizumab plasma levels after accelerated saturation in acquired haemophilia A.
    Kloeter T; Keller M; Metze M; Petros S; Pfrepper C
    Haemophilia; 2024 Jun; ():. PubMed ID: 38924184
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
    Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
    Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 39. Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres.
    Stonebraker JS; Ducore JM
    Haemophilia; 2021 Jan; 27(1):e22-e29. PubMed ID: 33012106
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.